Morra Enrica, Cesana Clara, Klersy Catherine, Varettoni Marzia, Cavanna Luigi, Canesi Bianca, Tresoldi Elisabetta, Barbarano Luciana, Lazzarino Mario
Department of Hematology and Bone Marrow Transplantation, Niguarda Ca' Granda Hospital, Milan, Italy.
Semin Oncol. 2003 Apr;30(2):172-7. doi: 10.1053/sonc.2003.50068.
The natural history of asymptomatic IgM monoclonal gammopathies (MG) and variables predicting evolution to symptomatic lymphoproliferative disorders were investigated in 452 patients diagnosed from 1975 to 2001. Univariate and multivariate Cox models were used to identify possible predictors of disease progression. At a median follow-up of 49 months (range, 12 to 233), 41 cases (9.1%) evolved to symptomatic Waldenstrom's macroglobulinemia (n = 36), non-Hodgkin's lymphoma (n = 2), B-cell chronic lymphocytic leukemia (n = 1), IgM multiple myeloma (n = 1), and primary amyloidosis (n = 1); the median interval from diagnosis was 53 months (range, 12 to 154). The cumulative probabilities of transformation into a symptomatic lymphoproliferative disease at 5 and 10 years were 8% (95% confidence interval [CI], 6% to 12%) and 21% (95% CI, 16% to 29%), respectively. At univariate analysis, monoclonal component size and hemoglobin level as continuous parameters, lymphocytosis (>4 x 10(9)/L), bone marrow lymphoplasmacytoid infiltration (>10%), erythrocyte sedimentation rate (>40 mm/h), and detectable Bence Jones proteinuria were significantly related with evolution probability. At multivariate analysis, paraprotein level (P <.0001), hemoglobin level (P <.05), and lymphocytosis (P <.0001) independently predicted malignant evolution (P <.0001). In conclusion, patients with asymptomatic IgM-MG showing hematological features predictive of progression should be carefully monitored in view of an early treatment of the disease.
对1975年至2001年诊断的452例无症状IgM单克隆丙种球蛋白病(MG)患者的自然病史以及预测向有症状淋巴增殖性疾病演变的变量进行了研究。采用单因素和多因素Cox模型来确定疾病进展的可能预测因素。中位随访49个月(范围12至233个月)时,41例(9.1%)患者进展为有症状的华氏巨球蛋白血症(n = 36)、非霍奇金淋巴瘤(n = 2)、B细胞慢性淋巴细胞白血病(n = 1)、IgM多发性骨髓瘤(n = 1)和原发性淀粉样变性(n = 1);从诊断到进展的中位间隔时间为53个月(范围12至154个月)。5年和10年时转化为有症状淋巴增殖性疾病的累积概率分别为8%(95%置信区间[CI],6%至12%)和21%(95%CI,16%至29%)。单因素分析时,作为连续参数的单克隆成分大小和血红蛋白水平、淋巴细胞增多(>4×10⁹/L)、骨髓淋巴浆细胞样浸润(>10%)、红细胞沉降率(>40 mm/h)以及可检测到的本周氏蛋白尿与进展概率显著相关。多因素分析时,副蛋白水平(P <.0001)、血红蛋白水平(P <.05)和淋巴细胞增多(P <.0001)独立预测恶性进展(P <.0001)。总之,鉴于对该疾病进行早期治疗,对于表现出预测进展的血液学特征的无症状IgM-MG患者应进行仔细监测。